Sickle Cell Disease-Modifying Therapies
Physicians, fellows, nurse practitioners, nurses, laboratory technicians, allied health professionals, and other healthcare professionals in the fields of pediatric hematology-oncology, transfusion medicine, and pathology need to receive regular updates on evidence-based approaches to the diagnosis and management of hematologic disorders and coagulopathies and on novel research findings. Reviews of challenging cases will be used as an impetus for discussion. The series aims to increase the knowledge and skills of the learners with regard to the spectrum of hematologic disorders and coagulopathies in order to enhance the quality of care and improve patient outcomes.
Physicians, fellows, nurses, and other healthcare professionals.
At the conclusion of the session, the participants should be able to:
Summarize the clinical course and chronic nature of sickle cell disease.
Describe historical and systemic barriers to innovative therapies for sickle cell disease.
Identify and differentiate between current and emerging therapies for sickle cell disease.
Baylor College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Baylor College of Medicine designates this enduring material activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation